1. Home
  2. KEN vs ABCL Comparison

KEN vs ABCL Comparison

Compare KEN & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Kenon Holdings Ltd.

KEN

Kenon Holdings Ltd.

HOLD

Current Price

$62.95

Market Cap

3.5B

Sector

Utilities

ML Signal

HOLD

Logo AbCellera Biologics Inc.

ABCL

AbCellera Biologics Inc.

HOLD

Current Price

$12.02

Market Cap

4.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KEN
ABCL
Founded
2014
2012
Country
Singapore
Canada
Employees
N/A
N/A
Industry
Electric Utilities: Central
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.5B
4.1B
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
KEN
ABCL
Price
$62.95
$12.02
Analyst Decision
Strong Buy
Analyst Count
0
12
Target Price
N/A
★ $16.82
AVG Volume (30 Days)
9.8K
★ 4.7M
Earning Date
12-02-2026
11-09-2026
Dividend Yield
★ 6.07%
N/A
EPS Growth
N/A
★ 10.91
EPS
★ N/A
N/A
Revenue
N/A
★ $75,128,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.12
P/E Ratio
$9.21
★ N/A
Revenue Growth
N/A
★ 160.56
52 Week Low
$48.23
$2.75
52 Week High
$95.93
$14.98

Technical Indicators

Market Signals
Indicator
KEN
ABCL
Relative Strength Index (RSI) 48.80 45.97
Support Level $58.89 $11.78
Resistance Level $70.27 $12.88
Average True Range (ATR) 1.26 0.75
MACD 0.34 -0.26
Stochastic Oscillator 61.19 8.65

Price Performance

Historical Comparison
KEN
ABCL

About KEN Kenon Holdings Ltd.

Kenon Holdings Ltd is a holding company that operates dynamic, growth-oriented businesses. The company's operating segments include: OPC Power Plants, which generates and supplies electricity and energy in Israel; and CPV Group, which generates and supplies electricity and energy in the United States. It generates maximum revenue from the OPC Power Plants segment, which generates and supplies electricity and energy in Israel. CPV Group is a limited partnership owned by OPC, which generates and supplies electricity and energy in the United States. Geographically, the company generates a majority of its revenue from Israel and the rest from the United States.

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.

Share on Social Networks: